Clinical Scorecard: Targeted Antibiotic Prophylaxis and Cotrimoxazole in Transrectal Prostate Biopsy: Findings from a Single-Center Investigation

At a Glance

Key Highlights

• Infectious complications occur in 2.8–7.6% of TRPB patients; perineal biopsy has lower infection rates but TRPB remains an option.
• European restrictions on fluoroquinolones have limited prophylaxis options; fosfomycin use is restricted.
• Empiric peri-interventional antibiotic prophylaxis (PAP) with cotrimoxazole (960 mg, four doses) is feasible and effective when rectal swabs and urine cultures are negative for multiresistant bacteria.

Guideline-Based Recommendations

Diagnosis

• Perform rectal swab to detect multiresistant gram-negative bacteria before biopsy.
• Obtain urine culture to identify bacteriuria or urinary tract infections prior to biopsy.

Management

• Use targeted antibiotics based on susceptibility testing if multiresistant bacteria or infection detected.
• Administer empiric cotrimoxazole prophylaxis (960 mg, four doses) if rectal swab and urine culture are negative.
• Adjust prophylaxis to meropenem or piperacillin + tazobactam single shot if multiresistant gram-negative bacteria detected.
• Treat urinary tract infections with susceptibility-guided antibiotics for 3–5 days peri-interventionally.

Monitoring & Follow-up

• Monitor patients for infectious complications within 21 days post-TRPB, including fever, dysuria, and severe prostate pain.
• Assess need for inpatient treatment, blood cultures, and intensive care admission if infection suspected.

Risks

• Risk of infectious complications due to rectal bacterial translocation during TRPB.
• Potential antibiotic resistance development with broad-spectrum antibiotic use.
• Limitations in prophylaxis options due to regulatory restrictions on fluoroquinolones and fosfomycin.

Patient & Prescribing Data

697 men undergoing TRPB for suspected prostate cancer at a single center

86% received empiric cotrimoxazole prophylaxis; 3% had multiresistant bacteria detected requiring targeted antibiotics; cotrimoxazole was effective in patients with negative rectal swab and urine cultures.

Clinical Best Practices

• Perform pre-biopsy rectal swab and urine culture to guide antibiotic prophylaxis.
• Use cotrimoxazole as empiric PAP in absence of multiresistant bacteria or urinary infection.
• Adjust antibiotic prophylaxis based on microbiological findings to reduce infectious complications and antibiotic resistance.
• Monitor patients closely for signs of infection post-biopsy and manage accordingly.

References

• European Association of Urology Guidelines on Prostate Biopsy
• German National Classification of Multiresistant Gram-negative Bacteria
• Restriction on Fluoroquinolones by European Commission